Abstract
EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of Patients With Metastatic Triple-Negative Breast Cancer in Greece
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have